ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
67.98
-0.56 (-0.82%)
As of 12:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close68.54
Open68.50
Bid67.87 x 1200
Ask67.86 x 800
Day's Range67.85 - 68.73
52 Week Range65.06 - 100.23
Volume4,467,931
Avg. Volume9,118,026
Market Cap100.5B
Beta (3Y Monthly)0.77
PE Ratio (TTM)19.36
EPS (TTM)3.51
Earnings DateJul 26, 2019
Forward Dividend & Yield4.28 (6.24%)
Ex-Dividend Date2019-07-12
1y Target Est84.92
Trade prices are not sourced from all markets
  • Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
    Zacks2 hours ago

    Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

    With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

  • Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?
    Zacks2 hours ago

    Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?

    While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

  • Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
    Zacks3 hours ago

    Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

    Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

  • Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
    MarketWatch3 hours ago

    Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect

    Celgene Corp., Biogen Inc., Bristol-Myers Squibb Co. and AbbVie Inc. are all scheduled to report earnings this week. Biogen is scheduled to report second-quarter earnings before the opening bell on Tuesday.

  • GuruFocus.com12 hours ago

    The Parnassus Fund Exits Mattel, Sells Alphabet

    Fund's largest sales of 2nd quarter Continue reading...

  • AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout
    Motley Foolyesterday

    AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout

    Here are AbbVie's grades on its previous acquisition deals. And they look ugly overall.

  • Better Buy: Pfizer vs. AbbVie
    Motley Foolyesterday

    Better Buy: Pfizer vs. AbbVie

    Which stock wins in a head-to-head matchup between these two big drugmakers?

  • 8 More Big Pharma Events in 2019 You Don't Want to Miss
    Motley Fool2 days ago

    8 More Big Pharma Events in 2019 You Don't Want to Miss

    These are the clinical trial readouts, FDA decisions, and blockbuster-drug launches that will set the tone for the entire industry.

  • GuruFocus.com3 days ago

    The 3 Top Stocks for Dividends Every Calendar Month

    By Samuel Smith Continue reading...

  • AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
    Zacks3 days ago

    AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

    AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
    Zacks3 days ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

    J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

  • 3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
    Zacks4 days ago

    3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

    Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

  • Novartis's Pure Play in Pharma Works, for Now
    Bloomberg4 days ago

    Novartis's Pure Play in Pharma Works, for Now

    (Bloomberg Opinion) -- Slimming down appears to be paying off for Novartis AG. CEO Vas Narasimhan has refocused the Swiss pharma giant around drugs by selling off eye-care business Alcon and its remaining consumer-health interests. Second-quarter earnings that beat Wall Street expectations Thursday and a big guidance boost showed the benefits of the strategy. Shares hit an all-time high in early trading even though the stock was already up over 20% year to date to that point and trades at a premium to peers. Novartis is benefiting from greater exposure to its drug business, which has more potential than the units it ditched. Simpler businesses are easier to understand and value, so it makes sense that the market has responded well to these moves. At this price, though, the strategy inherently exposes investors to more downside and volatility. The reason some drugmakers diversify is to add steadier revenue so they can better weather the booms, busts, and worrying product concentration that come with developing novel medicines. Novartis has a robust set of newer drugs, which is likely why it felt confident enough to get rid of other units. It has supplemented its arsenal further with a series of acquisitions as it continues its strategy by slimming down generic unit Sandoz.Psoriasis drug Cosentyx and heart medicine Entresto are the two drugs most key to the company’s near-term success. They helped drive the pharma unit’s 9 percent sales growth in the second quarter relative to the same period last year. There are high expectations for continuing growth, but they come with significant risks.A new rival from AbbVie Inc. recently entered the already crowded market Cosentyx competes in, and others are on the way. While Entresto has turned from a slow starter to a growing success story, a big chunk of its potential depends on expanding to new markets. Results are due from a late-stage trial in a new indication in the next few months. Positive indications will help justify the company’s current valuation. A failure could bring current momentum for the drug and Novartis’s more exposed stock screeching to a halt. Also, growth may not look as robust when sales begin to decline for two other blockbusters – cancer drug Afinitor and multiple sclerosis medicine Gilenya – in the next few years. That puts weight on the company’s most recent launches and pipeline. Those new products may be able to bear it; the company had a breast cancer drug, an MS medicine, and a groundbreaking gene therapy approved in the first half of the year. Late-stage data is due in the near term for potential blockbuster asthma and eye drugs as well as another MS drug. Still, weak launches or disappointing data could erode confidence in the company’s growth trajectory. Novartis executed its transition to a pure pharma firm well. There’s still a chance that the rapturous investor response is in part a sugar high. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • AC Immune Initiates Phase I Study for Alzheimer's Disease
    Zacks4 days ago

    AC Immune Initiates Phase I Study for Alzheimer's Disease

    AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

  • Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
    Zacks4 days ago

    Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

    Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

  • 3 Top Dividend Stocks With Yields Over 4%
    Motley Fool4 days ago

    3 Top Dividend Stocks With Yields Over 4%

    Check out why above-average dividend payers AT&T, AbbVie, and Harley-Davidson might be good long-term picks.

  • Should Value Investors Buy AbbVie (ABBV) Stock?
    Zacks5 days ago

    Should Value Investors Buy AbbVie (ABBV) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know
    Zacks5 days ago

    AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

    AbbVie (ABBV) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why
    Zacks5 days ago

    AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

    AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
    Zacks6 days ago

    AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

    AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

  • Zacks6 days ago

    J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

  • Barrons.com6 days ago

    Allergan Stock Won’t Rise Much More, Analyst Says, in Looking at Deal With AbbVie

    Bernstein analyst Ronny Gal says the spread between the current stock price and AbbVie’s offer is fair and it is time to take the foot off the gas.

  • AbbVie (ABBV) Gains But Lags Market: What You Should Know
    Zacks7 days ago

    AbbVie (ABBV) Gains But Lags Market: What You Should Know

    AbbVie (ABBV) closed at $70.29 in the latest trading session, marking a +0.01% move from the prior day.

  • Health care 'Cadillac Tax' repeal bill up for vote Wednesday
    Yahoo Finance Video5 days ago

    Health care 'Cadillac Tax' repeal bill up for vote Wednesday

    Congress will be voting Wednesday on a repeal of what is known as the “Cadillac Tax," which is a provision of the Affordable Care Act that would place a 40% tax on employer-sponsored health care plans that provide excess benefits. Yahoo Finance's Anjalee Khemlani breaks down what the provision does and what could come from the vote.

  • AbbVie Buys Allergan for $63 Billion
    Meredith Videos6 days ago

    AbbVie Buys Allergan for $63 Billion

    Allergan is the maker of Botox.